ProtAffin appoints Pfizer's Mike Bartley CDO
This article was originally published in Scrip
ProtAffin, a biotech developing a novel class of drugs for respiratory disease, inflammation and oncology, has appointed Dr Mike Bartley chief development officer, leading preclinical and clinical development activities. Dr Bartley previously served for 10 years at Pfizer, most recently as senior project leader for preclinical and clinical projects.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.